Stutzman Danielle L, Dopheide Julie A
Pediatric Mental Health Institute (DLS), Children's Hospital Colorado, Aurora, CO.
Department of Clinical Pharmacy (DLS), University of Colorado Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, CO.
J Pediatr Pharmacol Ther. 2024 Jun;29(3):215-231. doi: 10.5863/1551-6776-29.3.215. Epub 2024 Jun 10.
Over half of youth with attention-deficit/hyperactivity disorder (ADHD) have co-occurring psychiatric or medical conditions that present treatment challenges. Stimulants are the most effective pharmacologic treatment of ADHD for preschoolers to adults but questions about safety with co-occurring conditions frequently arise. In addition, stigma surrounding diagnosis and treatment can negatively impact care. This manuscript presents evidence-based practice pearls to guide treatment decisions for youth with ADHD and common coexisting psychiatric and medical conditions. Recommendations address specific stimulant adverse effects (i.e., anxiety, cardiac, growth, mania, psychosis) along with management strategies. Pearls were developed for the most common clinical questions, controversial topics, or therapeutic issues that may not be widely known. The goals of this manuscript are to: 1) provide a detailed resource for interprofessional teams regarding stimulant use in youth with ADHD, 2) improve therapeutic outcomes for youth with ADHD and co-occurring psychiatric and/or medical conditions through evidence-based recommendations, and 3) decrease stigma associated with stimulant use through education.
超过半数患有注意力缺陷多动障碍(ADHD)的青少年同时存在精神或躯体疾病,这给治疗带来了挑战。兴奋剂是治疗学龄前儿童至成人ADHD最有效的药物,但对于同时患有其他疾病时使用兴奋剂的安全性问题常常出现。此外,围绕诊断和治疗的污名化可能对治疗产生负面影响。本手稿介绍了基于证据的实用要点,以指导对患有ADHD以及常见并存精神和躯体疾病的青少年的治疗决策。建议涉及特定的兴奋剂不良反应(如焦虑、心脏问题、生长发育、躁狂、精神病性症状)以及管理策略。这些要点是针对最常见的临床问题、有争议的话题或可能不广为人知的治疗问题而制定的。本手稿的目的是:1)为跨专业团队提供有关在患有ADHD的青少年中使用兴奋剂的详细资源;2)通过基于证据的建议改善患有ADHD以及并存精神和/或躯体疾病的青少年的治疗效果;3)通过教育减少与使用兴奋剂相关的污名化。